Bernadette Porter MBE Clinical Lead NeuroResponse
& NIA Fellow

Bernadette is a Consultant MS Nurse at The National Hospital for Neurology and Neurosurgery, UCLH. She was awarded an MBE for services to nursing. Bernadette holds an MSc in Clinical Neuroscience and has published widely in academic journals. She is an advisor to a number of organisations including the RCN and RCP.

Bernadette has a track record of successfully and collaboratively challenging multidisciplinary teams to deliver patient focused care and is actively involved in service design and patient focused research agendas within UCL Partners.

Prizes awarded include The International MS Nurses Award for Excellence, British Journal of Nursing Award for Clinical Practice, the British Journal of Nursing Nurse of the Year included in the inaugural HSJ Top Innovators list in 2013 and winner of the Nursing Standard eHealth 2014.

 

Dr Jeremy Chataway Consultant Neurologist

Dr. Jeremy Chataway MA, PhD, FRCP Consultant Neurologist: National Hospital for Neurology and Neurosurgery, Queen Square, University College Foundation NHS Trust, London and St Mary’s Hospital (Imperial College Healthcare NHS Trust).

After qualifying in medicine at Cambridge and Oxford Universities, and general medical training in London, Dr. Chataway specialised in Neurology over an eight year period with posts in Edinburgh, Cambridge and London.

He was awarded a PhD from Cambridge University in genetic epidemiology of multiple sclerosis and took up his post as a consultant Neurologist in 2001 at St Mary’s Hospital (Imperial College Healthcare NHS Trust) and The National Hospital for Neurology and Neurosurgery, Queen Square, University College Foundation NHS Trust, London.

He has a particular interest in multiple sclerosis, in clinical trial work involving novel agents and advanced trial design, as well as service delivery.

Dr. Chataway currently sits on the MS Society Grant Review Panel for Care and Services Research and is a member of the Society’s Clinical Trials Network Steering Group.

Dr Robert Brenner Consultant Neurologist

Dr. Brenner is a highly experienced clinician having been a consultant neurologist for over 20 years. He combines the academic environment of the Royal Free hospital with the demands of a busy District General Hospital in West Herts. He is also an honorary Senior Lecturer at UCL and has a long involvement in MS research.

As the Lead Neurologist at RFH he has expertise in service design and is currently engaged in development of innovative reconfiguration of neurology provision with local CCGs.

He has been involved in the co-design of the NeuroResponse model contributing to the benchmark audit of Multiple Sclerosis service across the UCL partner region and the patient and family co-design events.

Conan O’Neill Digital Advisor and Operational Lead

Conan has 15 years’ experience in frontline operational delivery, including 3 years at Operations Director level.  In the past he has managed a range of services including GP out-of-hours, NHS 111, Urgent Treatment Centres and is responsible for setting up the first Integrated Urgent Care (IUC) service in England which went live in North Central London in 2016 and is available to 1.3 million patients in this area today.   His involvement in care delivery spans Community, Mental Health, Primary and Secondary care services.

Conan has significant expertise in codesigning, innovating and running patient- centred services across London.  In addition to his role supporting digital development and leading operational plans for NeuroResponse, Conan also holds the position of Head of Digital Delivery in Digital Development for NHS England, in which is he develops national strategy and digital innovation plans for the NHS.

Blu Reynolds Director of Operations LCW UCC (NeuroResposne Delivery Partner)

Blu is an experienced and pragmatic consultant with expertise in delivering complex change and transformation programmes in the UK health sector. Throughout his career, Blu has built strong client relationships, delivering numerous successful technology, process and pathway improvements across a broad range of NHS bodies (including commissioner and provider-side).

Blu specialises in change management, the design of new business processes and the definition of new operating models to drive the delivery of business transformation via complex, multi-organisation change programmes.

In 2017, Blu was appointed Director of Operations for a London provider of Integrated Urgent Care services providing care to 2.3 million people across North Central and North West London. In this role, Blu oversees multi-disciplinary teams to deliver a service portfolio of £25mn annually; developing strategies to innovate and deliver improvements to patient services.

Professor Alan M. Palmer FRSB, PhD, MSc, BSc
Commercial Advisor

Professor Alan Palmer has board level experience in several organisations. Currently, he is a non-executive director of One Nucleus Ltd (an international membership organisation for companies working within the life science and healthcare industry) and the British Neuroscience Association (the largest UK organisation representing and promoting neuroscience and neuroscientists). He is also a Trustee of The Brain Tumour Charity and one of the internationally recognised scientists that sits on the Welsh Government’s Sêr Cymru II Evaluation Panel.

Alan was one of the founders of the first UK neuroscience-based start-up company (Cerebrus Ltd, now Vernalis plc) and co-founded Pharmidex Pharmaceutical Services Ltd, a successful contract research organisation working in the medicines research arena. He was voted London Biotechnology Network Entrepreneur of the Year in 2005.

Alan is a visiting Professor at University College London and the University of Reading and Life Science Entrepreneur in Residence at the University of Bristol. He is also a Fellow of the Royal Society of Biology and an Honorary member of the Society for Medicines Research.

Alan has a BSc in Biochemistry from Warwick University, an MSc from Kings College London (Institute of Psychiatry) and a PhD from University College London (Institute of Neurology).